TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04968262

Intervention type: OTHER
Intervention: Sepsis therapy
Description: Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.

Intervention type: OTHER
Intervention: Sepsis-related acute kidney injury therapy
Description: Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
Study: NCT00054964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol HFA-BOI
Description: Albuterol HFA breath operated inhaler, 90 mcg/sprau

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA-MDI
Description: Albuterol HFA multi-dose inhaler
Study: NCT03462706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare
Description: Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot Snare
Description: Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold EMR
Description: Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot EMR
Description: Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
Study: NCT04805463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF group
Description: The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGF group
Description: The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFG group
Description: The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
Study: NCT05260372

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of donor-derived cell-free DNA
Description: Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
Study: NCT01411501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride citrate
Description: 4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
Study: NCT02231229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCR-based strategy
Description: Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
Study: NCT03842462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: infants receive primary non-invasive respiratory support by mean of nCPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: infants receive primary non-invasive respiratory support by mean of NIPPV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: infants receive primary non-invasive respiratory support by mean of NHFOV
Study: NCT01062763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: 25 to 50 mg once daily
Study: NCT03368885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mobilization
Description: Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacity Building
Description: Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
Study: NCT01062763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: addition of placebo 1 to 2 tablets daily
Study: NCT01712243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light
Study: NCT01403441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiosurgical Neuromodulation using the Cyberknife
Description: our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
Study: NCT02542540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with Nintendo Wii console
Description: Children with OI and draining for 3 months using Nintendo Wii console
Study: NCT02020980

Intervention type: BIOLOGICAL
Intervention: Botulinum toxin type A
Description: This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines.
Study: NCT02896816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface EMG, MRI and PET Scan
Description: It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surface EMG
Description: It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
Study: NCT01556698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study: NCT02392611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alobresib
Description: Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
Study: NCT03743896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Glucosamine Cream
Study: NCT01334944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Study: NCT02387437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SI recruitment
Description: SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SI recruitment
Description: SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SI recruitment
Description: SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP recruitment
Description: Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP recruitment
Description: Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP recruitment
Description: Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCV recruitment
Description: PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCV recruitment
Description: PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCV recruitment
Description: PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
Study: NCT00803166

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of three days

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of three days

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test product 1
Description: Small amount applied and evaluated over the course of three days

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test product 1
Description: Small amount applied and evaluated over the course of three days

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test Product 2
Description: Small amount applied and evaluated over the course of three days

Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Cream-Test Product 2
Description: Small amount applied and evaluated over the course of three days
Study: NCT04068363

Intervention type: OTHER
Intervention: non interventional
Description: non interventional study

Intervention type: OTHER
Intervention: non interventional
Description: non interventional study
Study: NCT03260127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized executive function training plus CPT (CEFT-CPT)
Description: Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Word game training plus CPT (WT-CPT)
Description: Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
Study: NCT02803060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
Study: NCT03325205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
Study: NCT04380298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30ml of local infiltration solution containing 60mg ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study: NCT03394456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes program
Description: Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth training and support for Community Health Workers
Description: weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
Study: NCT04297787

Intervention type: DEVICE
Group type: OTHER
Intervention: Thrombolysis in combination with endhole aspiration
Description: The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
Study: NCT04651114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-making tool
Description: Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision.
Study: NCT01713699

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture
Study: NCT02674932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying and Using Signature Strengths
Description: The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Identifying and Writing Down Coping Skills
Description: The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
Study: NCT04169919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Povidone-Iodine 5% eye wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush
Description: Normal Saline eye wash